Inflarx NV (NASDAQ:IFRX) was the recipient of a large growth in short interest in June. As of June 30th, there was short interest totalling 1,242,600 shares, a growth of 32.0% from the May 30th total of 941,700 shares. Based on an average daily volume of 1,560,000 shares, the short-interest ratio is presently 0.8 days. Approximately 8.2% of the company’s shares are short sold.
Shares of IFRX traded down $0.04 during trading hours on Friday, reaching $3.24. 733,035 shares of the company traded hands, compared to its average volume of 1,270,417. The firm has a fifty day moving average price of $11.08. The stock has a market cap of $85.16 million, a P/E ratio of -2.31 and a beta of -1.52. Inflarx has a 12 month low of $2.91 and a 12 month high of $53.10.
Inflarx (NASDAQ:IFRX) last announced its earnings results on Thursday, May 23rd. The company reported ($0.43) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.19. As a group, equities analysts expect that Inflarx will post -2.09 EPS for the current year.
A number of brokerages have recently weighed in on IFRX. Raymond James reaffirmed a “buy” rating on shares of Precision Drilling in a research note on Wednesday, June 5th. ValuEngine lowered shares of Zosano Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, May 1st. JPMorgan Chase & Co. set a $69.00 target price on shares of Helmerich & Payne and gave the company a “buy” rating in a research note on Wednesday, June 5th. SunTrust Banks lowered shares of Inflarx from a “buy” rating to a “hold” rating and cut their target price for the company from $55.00 to $5.00 in a research note on Wednesday, June 5th. Finally, Leerink Swann lowered shares of Inflarx from an “outperform” rating to a “market perform” rating in a research note on Wednesday, June 5th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and one has assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $15.72.
Inflarx Company Profile
InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.
Further Reading: Momentum Indicators
Receive News & Ratings for Inflarx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inflarx and related companies with MarketBeat.com's FREE daily email newsletter.